Pattern of disease and response to pembrolizumab in recurrent cervical cancer

OBJECTIVE: Since the approval of pembrolizumab for advanced or recurrent PD-L1 positive (CPS > 1%) cervical cancer, the clinical characteristics associated with response have remained undefined. We sought to characterize the clinicopathologic features of patients with advanced cervical cancer at...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gynecol Oncol Rep
Hlavní autoři: Miller, Kathryn M., Filippova, Olga T., Hayes, Sara A., Abu-Rustum, Nadeem R., Aghajanian, Carol, Broach, Vance, Ellenson, Lora H., Selenica, Pier, Jewell, Elizabeth L., Kyi, Chrisann, Lakhman, Yuliya, Mueller, Jennifer J., O'Cearbhaill, Roisin E., Park, Kay J., Sonoda, Yukio, Zamarin, Dmitriy, Weigelt, Britta, Leitao, Mario M., Friedman, Claire F.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2021
Témata:
Research Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8319446/
https://ncbi.nlm.nih.gov/pubmed/34345644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2021.100831
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky